Pharvaris N.V.
deucrictibant
hereditary angioedema (HAE)
Resolved
188days ago
Phase 3 readout · Dec 31, 2025
What's at stake
Phase 3 trial results for deucrictibant in hereditary angioedema (HAE) are due Dec 31, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“Enrollment in CREAATE ( NCT07266805 ) progressing as planned.”